Public Companies
Origin Therapeutics To Buy Safe Supply Streaming
Origin Therapeutics Holdings Inc. (CSE:ORIG) is buying Safe Supply Streaming Co. Ltd. as per a binding LOI with a formal agreement expected by the end…
Origin Therapeutics Holdings Inc. (CSE:ORIG) is buying Safe Supply Streaming Co. Ltd. as per a binding LOI with a formal agreement expected by the end of February. Origin is an investment issuer that has historically focused on making equity investments in psychedelics-industry-related. It should be noted that in December 2022 Origin announced that its board of directors had initiated a review process to consider, review and evaluate strategic alternatives for the company.
Safe Supply will complete an arm’s length equity financing of at least $3 million and no greater than $4 million subscription receipts ultimately exchangeable into Resulting Issuer Shares. The proceeds from the Private Placement will be used to fund working capital and general corporate purposes, including potential streaming investments.
Upon closing of the Private Placement, the Resulting Issuer will have more than $6 million in cash to execute its business plan. Origin has agreed to lend up to $500,000 as interim financing to Safe Supply to allow Safe Supply to execute near-term business objectives.
Safe Supply is a pharmaceutical streaming and investment company tackling the global safe supply ecosystem. Safe Supply has a portfolio of potential letters of intent for investments across the value chain from narcotics licenses to laboratories to clinics and more.
Recently, Health Canada and British Columbia’s provincial governments moved to decriminalize certain schedule 1 narcotics marking the third and the final wave of de-scheduling in Canada in its movement to fight the healthcare crisis. The safe supply of cannabis and legalization started in 2013 in Canada. Following the success of cannabis legalization, in 2019 the Canadian government launched the second wave of de-scheduling narcotics with psychedelics and psychedelic-assisted therapy. The company said in a statement, “This third and final wave of de-scheduling marks a monumental period for the country and presents a unique opportunity for investors and commercial operators to work with the Canadian government to advance their efforts.”
The post Origin Therapeutics To Buy Safe Supply Streaming appeared first on Green Market Report.
psychedelics psychedelic origin therapeutics health canada legalization-
Law & Regulation1 week ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics7 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
-
Psychedelics6 days ago
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
-
Law & Regulation1 week ago
AbbVie, Gilgamesh Pharmaceuticals enter psychiatric drug deal
-
Law & Regulation6 days ago
FDA nod fuels Filament’s psychedelics push, but cash running short
-
Psychedelics7 days ago
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
-
Psychedelics6 days ago
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
-
Psychedelics6 days ago
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules